Table 1:

Patient Characteristics

Subject ID	Age (Years)	Clinical Stage at Diagnosis	PSA at Time of Treatment (ng/mL)	Gleason Score	Sites of Metastatic Disease	Time from Diagnosis to Metastatic Disease (Months)	Time from Metastatic Disease to CRPC (Months)	Prior Treatment History
Patient 2	55	IV	237.8	n/a	Bo, Bl	0a	12	c†,d,e,f,g†,i
Patient 4	50	IV	7.6	9	LN	0a	12	c†,d,e,f,g†
Patient 5	71	IV	10.47	7	LN	108	46	c,d,e
Patient 6	72	IV	41.6	9	LN	24	30	b,c,d,e
Patient 7	73	IV	331.2	9	Bo	3	15	b,d,e,g
Patient 8	64	III	132.3	7	Bl	48	36	c,d,e,g,i
Patient 9	71	III	36.6	7	Bo, LN	96	18	b,c,e,h,i
Patient 11	72	IV	15.5	7	Bo, LN	0a	144	b,e,h
Patient 12	67	III	13.4	7	LN	12	24	b,c,d,e
Patient 14	70	II	14.6	7	Bo	18	28	b,c,d,e
Patient 16	58	IV	1683	n/a	Bo, LN	0a	11	e,g†
Patient 17	56	III	5.2	9	Bo	17	20	b,c†,e
Patient 18	73	IV	973	9	Li	0a	22	d,e,g†,i

n/a = not applicable

Sites of Metastatic Disease: Bl, bladder; Bo, bone; LN, lymph nodes; Li, liver

^aPatient presented with metastatic disease at time of diagnosis

Prior Treatment History:

^bprostatectomy;

^cradiation therapy;

^c†radiation therapy with palliative intent;

^dfirst generation anti-androgen;

^enovel androgen receptor signaling inhibitor;

^fbone supportive care;

^gdocetaxel;

^g†docetaxel in the setting of mCSPC;

^hSipuleucel-T;

ⁱother

Note: In the ‘other’ category, Patient 9 received experimental seviteronel/dexamethasone therapy.